earnings
confidence high
sentiment positive
materiality 0.75
Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance
BIOGEN INC.
2022-Q3 EPS reported
$17.07
revenue$7,629,400,000
- Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).
- GAAP diluted EPS $7.84; Non-GAAP diluted EPS $4.77.
- Lecanemab Phase 3 Clarity AD met primary endpoint and all key secondary endpoints in early Alzheimer's.
- Tofersen NDA accepted with priority review; PDUFA date April 25, 2023.
- Company raises full year 2022 financial guidance.